BioSpace News Archive

Vifor Pharma Group today announced the divestment of its finished drug product manufacturing business to CordenPharma.

Novadiscovery expands Janssen collaboration by implementing its JINKO ® clinical trial simulation platform for the development of lung cancer models Janssen intends to use computational disease models to investigate benefits of in silico trials on Non-Small cell lung cancer.

Anaveon, a clinical-stage immuno-oncology company, announced that it has agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments, Pfizer Ventures and Pontifax.

Novaliq provided a development update on the phase 3 trial of SHR8058 eye drops for the treatment of dry eye disease associated with Meibomian gland dysfunction conducted by Jiangsu Hengrui Pharmaceuticals Co., Ltd. in the People’s Republic of China showing statistically significant topline results compared to 0.6% sodium chloride solution.[1].

Antengene Corporation Limited and XtalPi Inc announced today a long-term R&D collaboration.

ZOLL® Medical Corporation announced that it has successfully completed its previously announced acquisition of Itamar™ Medical Ltd., a medical device and digital health company that provides at-home testing for sleep apnea.

Quipt Home Medical Corp. is very pleased to announce record preliminary financial results for the fourth quarter of 2021, ending September 30, 2021 as well as a business update with respect to recent announcements.

Axcella Therapeutics today announced that patient screening is now underway in a Phase 2a trial that is investigating AXA1125, an oral product candidate, as a potential treatment for Long COVID, also known as Post COVID-19 Condition and post-acute sequelae of SARS-COV-2 infection (PASC).

Cyteir Therapeutics, Inc. today announced the appointment of Dr. Jeffrey S. Humphrey, MD, Chief Medical Officer of Magenta Therapeutics to its Board of Directors.

Vaxart, Inc. (NASDAQ: VXRT) said today it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant in two different studies expected to begin next month.